Regeneron and Trump Administration Finalize Drug Pricing Deal with Free Gene Therapy
Regeneron has reached an agreement with the Trump administration to lower drug prices for some Americans, as part of a broader effort to tie U.S. drug prices to those in other developed nations. The deal includes offering the first hearing-loss gene therapy, Otarmeni, for free to eligible U.S. patients. This agreement is part of President Trump's 'Most Favored Nation' initiative, which aims to reduce healthcare costs by securing pricing concessions from pharmaceutical companies. The deal also provides tariff relief for Regeneron, exempting the company from certain planned levies. 
